Iberdomide Triplet Extends Progression Free Survival in Myeloma
Bristol Myers Squibb reported that the Phase 3 EXCALIBER-RRMM trial met its progression-free survival dual-primary endpoint for iberdomide plus subcutaneous daratumumab and dexamethasone (ZDd). Median progression-free survival was 42 months versus 20 months with…
